Pages
Products
Syn-mCherry AAV (Serotype Retrograde)

Syn-mCherry AAV (Serotype Retrograde)

Cat.No. :  AAV00326Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV serotype Retrograde Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00326Z
Description Prepackaged AAV particles in serotype retrograde containing mCherry reporter gene under the control of human Synapsin promoter.
Serotype AAV serotype Retrograde
Target Gene mCherry
Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

Viral vectors can be used to study the structure and function of the central nervous system (CNS). Adeno-associated virus (AAV) is widely used to deliver genes to the CNS because it is non-pathogenic. AAV is a small virus belonging to the Parvoviridae family that requires co-infection with a helper virus for replication. More than 100 AAV variants have been found in human and non-human primate tissues. Recombinant AAV is produced by replacing all viral genomes between the nucleotide terminal inverted repeat sequences with a transcription cassette less than approximately 5 kb in length. AAV is a non-enveloped, single-stranded DNA virus belonging to the Parvoviridae family. So far, dozens of AAV serotypes have been identified, each of which exhibits a unique tissue tropism, which is mainly determined by its capsid. However, most of them lack the ability to infect axons and transport retrogradely to the cell body, which limits their application in retrograde neuronal tracing and circuit interrogation. In 2016, Trevo et al. described a new AAV variant, rAAV2-retro, with robust performance in retrotransduction by directed evolution of a capsid library. They found that the virus with capsid mutations N382D, V708I and the insertion of LADQDYTKTA at position 587 showed the highest efficiency. The retrotransduction function was increased by nearly two orders of magnitude compared to its parent, which emphasizes the importance of these capsid mutations in acquiring new transduction properties.

Acute itch is a protective system that warns the body of the presence of external irritants, whereas chronic itch is a debilitating but poorly treated clinical disorder that results in repetitive scratching and skin damage. Here, researchers identify a cell type-dependent role played by the anterior cingulate cortex (ACC) in controlling chronic itch-associated excessive scratching behavior in mice. Furthermore, researchers describe a neural circuit that originates from excitatory neurons in the ACC and extends to the ventral tegmental area (VTA) that is critically involved in chronic itch. The ACC→VTA circuit also selectively modulates histaminergic acute itch. Finally, ACC neurons were shown to predominantly innervate non-dopaminergic neurons of the VTA. These findings reveal a cortical-midbrain circuit underlying chronic itch-induced scratching behavior and provide new insights for therapeutic intervention.

Previous studies have demonstrated a reciprocal inter-connection between ACC and VTA. Human imaging studies have shown that both regions are involved in itch processing. Therefore, the researchers wondered whether the ACC→VTA projection could be activated by chronic pruritogenic stimuli. To this end, AAV-Retro-hSyn-mCherry was injected into the VTA, and co-staining of c-Fos expression with mCherry was tested 4 weeks later (Figure 3A-C). The total number of mCherry+ neurons in the diphenylcyclopropenone (DCP) group was found to be no different from that in the control group (Figure 3D, E). However, animals treated with DCP had more c-Fos+/mCherry+ neurons (Figure 3F, G). In addition, DCP triggered an increase in the percentage of c-Fos+/mCherry+ neurons in all bregma planes of the ACC (Figure 3H). These data indicate a dramatic activation of the ACC neurons projecting to the VTA under the conditions of chronic itch.

Activation of the ACC-VTA excitatory projection by chronic itch.Figure 1. Activation of the ACC→VTA excitatory projection by chronic itch. (Zhang T T, et al., 2023)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Reliable results

The Syn-mCherry AAV (Serotype Retrograde) from Creative Biogene integrates effortlessly into our gene therapy pipelines, enhancing our research accuracy with its robust expression levels.

United Kingdom

01/08/2022

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

CBpromise

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER